Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zoloft PTSD Claim Clears FDA Cmte.; More Studies In Men Sought

Executive Summary

Additional trials of Pfizer's Zoloft (sertraline) in post-traumatic stress disorder should focus on the drug's treatment benefit in men, FDA's Psychopharmacologic Drugs Advisory Committee said Oct. 8. The committee recommended approval of the product for PTSD.

You may also be interested in...

Post Traumatic Stress Disorder Trials Should Use Fixed Dose, Committee Says

Sponsors seeking a post traumatic stress disorder indication should conduct fixed-dose studies, FDA's Psychopharmacologic Drugs Advisory Committee advised during its Oct. 8 review of Pfizer's Zoloft.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts